Association between Modified <italic style="font-style: italic">Yiqi Huoxue Jiedu Formula</italic> （益气活血解毒方） or PARP Inhibitors Maintenance Therapy and Recurrence and Metastasis in Advanced Ovarian Cancer：A Propensity Score Matched Case-Control Study

CUI Yongjia; LU Wenping; CHANG Lei; WEI Yilin; WANG Xiyue

doi:10.13288/j.11-2166/r.2025.03.008

您当前的位置：

首页 >

文章列表页 >

Association between Modified Yiqi Huoxue Jiedu Formula （益气活血解毒方） or PARP Inhibitors Maintenance Therapy and Recurrence and Metastasis in Advanced Ovarian Cancer：A Propensity Score Matched Case-Control Study

更新时间：2025-01-26

- Association between Modified Yiqi Huoxue Jiedu Formula （益气活血解毒方） or PARP Inhibitors Maintenance Therapy and Recurrence and Metastasis in Advanced Ovarian Cancer：A Propensity Score Matched Case-Control Study
  增强出版
- Journal of Traditional Chinese Medicine Vol. 66, Issue 3, Pages: 256-261(2025)
- 作者机构：
  
  1.中国中医科学院广安门医院，北京市西城区北线阁5号，100053
  2.中国中医科学院博士后科研流动站
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2025.03.008
  CLC：
- Received：17 April 2024，
  
  Revised：2024-11-07，
  
  Published：02 February 2025
- 稿件说明：
移动端阅览
崔永佳,卢雯平,常磊等.益气活血解毒方加减或PARP抑制剂维持治疗与晚期卵巢癌复发转移的相关性——基于倾向性评分匹配的病例对照研究[J].中医杂志,2025,66(03):256-261.

CUI Yongjia,LU Wenping,CHANG Lei,et al.Association between Modified Yiqi Huoxue Jiedu Formula （益气活血解毒方） or PARP Inhibitors Maintenance Therapy and Recurrence and Metastasis in Advanced Ovarian Cancer：A Propensity Score Matched Case-Control Study[J].Journal of Traditional Chinese Medicine,2025,66(03):256-261.
崔永佳,卢雯平,常磊等.益气活血解毒方加减或PARP抑制剂维持治疗与晚期卵巢癌复发转移的相关性——基于倾向性评分匹配的病例对照研究[J].中医杂志,2025,66(03):256-261. DOI： 10.13288/j.11-2166/r.2025.03.008.

CUI Yongjia,LU Wenping,CHANG Lei,et al.Association between Modified Yiqi Huoxue Jiedu Formula （益气活血解毒方） or PARP Inhibitors Maintenance Therapy and Recurrence and Metastasis in Advanced Ovarian Cancer：A Propensity Score Matched Case-Control Study[J].Journal of Traditional Chinese Medicine,2025,66(03):256-261. DOI： 10.13288/j.11-2166/r.2025.03.008.

摘要

目的

探讨益气活血解毒方加减或多腺苷二磷酸核糖聚合酶（PARP）抑制剂维持治疗与卵巢癌复发转移的相关性。

方法

采用病例对照研究方法，根据卵巢癌患者一线维持治疗之后是否出现复发转移分为两组，出现复发转移者为病例组，未出现复发转移者为对照组。将既往一线维持治疗方式设定为研究的暴露因素（使用益气活血解毒方加减定义为暴露，使用PARP抑制剂定义为未暴露）。收集两组患者基线资料，包括R0手术切除、年龄、分期、是否行新辅助化疗、是否淋巴结转移、是否胚系BRCA1/2突变、是否存在同源重组修复缺陷、一线维持治疗方式（益气活血解毒方加减或PARP抑制剂）、末次化疗后CA125水平，对两组患者上述基线资料进行差异性检验，若存在差异，采用1∶1邻近匹配法进行倾向性评分匹配，采用单因素和多因素Logistic回归分析方法分析益气活血解毒方加减或PARP抑制剂与卵巢癌复发转移的相关性。

结果

共纳入201例晚期卵巢癌患者，其中病例组97例，对照组104例。两组患者在R0手术切除、分期、行新辅助化疗、末次化疗后CA125水平差异具有统计学意义（

＜0.05），提示两组患者基线不均衡。进一步经倾向性评分匹配后，病例组和对照组各有71例患者，两组患者基线均衡（

＞0.05）。单因素Logistic回归分析结果显示，R0手术切除（

=0.006）、分期（

=0.001）、行新辅助化疗（

=0.024）、一线维持治疗方式（

=0.006）、末次化疗后CA125水平（

=0.013）与卵巢癌的复发转移相关。多因素Logistic回归分析结果显示，分期是影响卵巢癌复发转移的独立影响因素（

=0.030），而一线维持治疗方式与卵巢癌的相关性

值为0.188。

结论

卵巢癌患者一线维持治疗使用益气活血解毒方加减或PARP抑制剂与卵巢癌复发转移不具有相关性。

Abstract

Objective

To investigate the association between the maintenance treatment of modified

Yiqi Huoxue Jiedu Formula

（益气活血解毒方） or poly ADP ribose polymerase （PARP） inhibitors and the recurrence and metastasis of advanced ovarian cancer.

Methods

A case-control study design was employed， dividing patients with advanced ovarian cancer into two groups based on the occurrence of recurrence and metastasis following first-line maintenance treatment. Patients with recurrence and metastasis comprised the case group， while those without recurrence and metastasis served as the control group. The previous first-line maintenance treatment method was set as the exposure factor in the study （with the use of modified

Yiqi Huoxue Jiedu Formula

defined as exposed and PARP inhibitors defined as unexposed）. Basic information was collected for both groups， including the achievement of satisfactory R0 surgery， age， stage， neoadjuvant chemotherapy， lymph node metastasis， germline BRCA1/2 mutations， homologous recombination deficiency positivity， first-line maintenance treatment method （modified

Yiqi Huoxue Jiedu Formula

or PARP inhibitors）， and CA125 levels after the last chemotherapy. The baseline data of the two groups we

re assessed for differences. If there exists difference， a 1∶1 nearest neighbor matching method was used for propensity score matching. Univariate and multivariate logistic regression analyses were employed to evaluate the association between the modified

Yiqi Huoxue Jiedu Formula

or PARP inhibitors and the recurrence and metastasis of ovarian cancer.

Results

A total of 201 patients with advanced ovarian cancer were included， with 97 in the case group and 104 in the control group. Both groups showed statistically significant differences in R0 surgery， stage， neoadjuvant chemotherapy， and CA125 levels after the last chemotherapy （

＜0.05）， indicating baseline imbalance. After propensity score matching， there were 71 patients in both the case and control groups， achieving baseline balance （

＞0.05）. Univariate logistic regression analysis indicated that the achievement of satisfactory R0 surgery （

= 0.006）， disease stage （

= 0.001）， the use of neoadjuvant chemotherapy （

= 0.024）， treatment modality （

= 0.006）， and CA125 levels after the last chemotherapy （

= 0.013） were associated with the recurrence and metastasis of ovarian cancer. Multivariate logistic regression analysis revealed that disease stage was an independent influencing factor for the recurrence and metastasis of ovarian cancer （

= 0.030）， whereas the

-value for the correlation between first-line maintenance treatment and ovarian cancer was 0.188.

Conclusion

First-line maintenance treatment of ovarian cancer patients with the use of modified

Yiqi Huoxue Jiedu Formula

or PARP inhibitors does not correlate with the recurrence and metastasis of ovarian cancer.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

KURNIT KC ， FLEMING GF ， LENGYEL E . Updates and new options in advanced epithelial ovarian cancer treatment ［J］. Obstet Gynecol ， 2021 ， 137 （ 1 ）： 108 - 121 .

KONSTANTINOPOULOS PA ， MATULONIS UA . Clinical and translational advances in ovarian cancer therapy ［J］. Nat Cancer ， 2023 ， 4 （ 9 ）： 1239 - 1257 .

中华医学会妇科肿瘤学分会 . 卵巢癌PARP抑制剂临床应用指南（2022版）［J］. 现代妇产科进展， 2022 ， 31 （ 8 ）： 561 - 572 .

GONZÁLEZ-MARTÍN A ， POTHURI B ， VERGOTE I ， et al . Niraparib in patients with newly diagnosed advanced ovarian cancer ［J］. N Engl J Med ， 2019 ， 381 （ 25 ）： 2391 - 2402 .

DISILVESTRO P ， BANERJEE S ， COLOMBO N ， et al . Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation： the SOLO1/GOG 3004 trial ［J］. J Clin Oncol ， 2023 ， 41 （ 3 ）： 609 - 617 .

LAFARGUE CJ ， MOLIN GZDAL ， SOOD AK ， et al . Exploring and comparing adverse events between PARP inhibitors ［J］. Lancet Oncol ， 2019 ， 20 （ 1 ）： e15 - e28 .

卢雯平 . 从三焦膜腠理论探析晚期卵巢癌-腹膜转移及中医维持治疗［J］. 肿瘤防治研究， 2022 ， 49 （ 8 ）： 756 - 759 .

张炜玄，姜奕慈，卢雯平，等 . 中医全程管理卵巢癌思路探析［J］. 中国中医药信息杂志， 2024 ， 31 （ 5 ）： 157 - 161 .

李怡帆 . 益气活血解毒方治疗晚期卵巢癌的临床疗效观察及其机制探讨［D］. 北京：北京中医药大学， 2017 .

LI Y ， LI J ， FAN B ， et al . Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients： a double-blind randomized controlled clinical trial ［J］. J Tradit Chin Med ， 2020 ， 40 （ 1 ）： 103 - 111 .

中国抗癌协会妇科肿瘤专业委员会 . 卵巢恶性肿瘤诊断与治疗指南（第四版）［J］. 中国实用妇科与产科杂志， 2018 ， 34 （ 7 ）： 739 - 749 .

RUSTIN GJ ， VERGOTE I ， EISENHAUER E ， et al . Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup （GCIG）［J］. Int J Gynecol Cancer ， 2011 ， 21 （ 2 ）： 419 - 423 .

廖慧妍，肖静 . 上皮性卵巢癌生化复发的判定、随访及治疗研究进展［J］. 现代肿瘤医学， 2023 ， 31 （ 14 ）： 2714 - 2719 .

中国医师协会中西医结合医师分会，中国中西医结合学会循证医学专业委员会 . 中医药与中西医结合临床研究方法指南［J］. 中国中西医结合杂志， 2015 ， 35 （ 8 ）： 901 - 932 .

张庆林，刘丽星，李淏，等 . 中医药治疗对晚期卵巢癌减瘤术后患者远期生存的影响［J］. 中医学报， 2023 ， 38 （ 1 ）： 192 - 197 .

卢雯平，马丹，闫会苓，等 . 晚期卵巢癌常规治疗后中医维持治疗的疗效分析［J］. 国际中医中药杂志， 2014 ， 36 （ 1 ）： 13 - 16 .

黎卓涵，王艳萍，蔡娱飞 . 中医药治疗卵巢癌及并发症的优势分析［J］. 吉林中医药， 2022 ， 42 （ 12 ）： 1469 - 1472 .

宋清雅，卢雯平 . 基于三焦膜腠理论探析卵巢癌的病机与辨治［J］. 中医杂志， 2024 ， 65 （ 20 ）： 2097 - 2101 .

SCHOUTROP E ， MOYANO-GALCERAN L ， LHEUREUX S ， et al . Molecular， cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment ［J］. Semin Cancer Biol ， 2022 ， 86 （ Pt 3 ）： 207 - 223 .

HAO D ， LI J ， JIA S ， et al . Integrated analysis reveals tubal- and ovarian-originated serous ovarian cancer and predicts differential therapeutic responses ［J］. Clin Cancer Res ， 2017 ， 23 （ 23 ）： 7400 - 7411 .

郭子瑗，冯蓉，邱景，等 . 从三焦形质探讨其在肿瘤转移的病机［J］. 云南中医中药杂志， 2021 ， 42 （ 4 ）： 9 - 12 .

叶乃菁，刘宣，李琦 . 癌毒转移的中医理论探讨［J］. 中医杂志， 2014 ， 55 （ 3 ）： 185 - 188 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Characteristics of the Five Tones of Parkinson's Disease Patients Based on the Theory of "Five-Viscera Phonology"：A Case-Control Study

Analysing the Pathogenesis and Treatment of Ovarian Cancer Based on the Theory of "Sanjiao Membrane and Interstice"

The Correlation between Traditional Chinese Medicine Constitution and the Progression of Abnormal Glucose Metabolism in Community Population： A Case-control Study

PIAO Bingkui’s Experience in Treating Ovarian Cancer

Experience of WU Liangcun in Treating Ovarian Cancer

Related Author

YANG Minghui

LI Shaodan

LI Min

WANG Xuelin

Yang Wenxue

SONG Qingya

CHEN Qingguang

LU Hao

Related Institution

Department of Traditional Chinese Medicine，the Sixth Medical Centre，the People's Liberation Army General Hospital and Medical School

Qingdao Navy Special Recreation Centre

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

中国中医科学院广安门医院

First Clinical Medical School,Zhejiang University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Association between Modified Yiqi Huoxue Jiedu Formula （益气活血解毒方） or PARP Inhibitors Maintenance Therapy and Recurrence and Metastasis in Advanced Ovarian Cancer：A Propensity Score Matched Case-Control Study

DOI：10.13288/j.11-2166/r.2025.03.008

摘要

Abstract

关键词

Keywords

references